Drug Information: Milrinone
Milrinone is a phosphodiesterase-3 (PDE3) inhibitor used as an inotropic agent to increase cardiac output. It works by inhibiting the breakdown of cyclic AMP (cAMP) in cardiac and vascular smooth muscle cells. This results in increased intracellular cAMP, leading to enhanced contractility in the heart and vasodilation in the blood vessels. Milrinone is typically administered intravenously in hospital settings to manage acute heart failure and cardiogenic shock, providing short-term support to the failing heart.
Category
Inotrope
Mechanism of Action
Milrinone exerts its therapeutic effects through the inhibition of phosphodiesterase-3 (PDE3). PDE3 is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) within cardiac and vascular smooth muscle cells. By inhibiting PDE3, milrinone prevents the breakdown of cAMP, leading to an increase in intracellular cAMP levels.
In cardiac muscle cells, elevated cAMP activates protein kinase A (PKA), which subsequently phosphorylates various proteins involved in cardiac contractility. Specifically, phosphorylation of L-type calcium channels enhances calcium influx, increasing the availability of calcium for binding to troponin C. This, in turn, strengthens the interaction between actin and myosin filaments, resulting in enhanced myocardial contractility, a positive inotropic effect.
In vascular smooth muscle cells, increased cAMP levels also activate PKA, which phosphorylates myosin light chain kinase (MLCK). Phosphorylation of MLCK reduces its affinity for calcium-calmodulin, thus inhibiting the phosphorylation of myosin light chains. This leads to smooth muscle relaxation and vasodilation. The vasodilation induced by milrinone reduces both preload and afterload on the heart, improving cardiac output and reducing myocardial oxygen demand. The combined inotropic and vasodilatory effects of milrinone make it a valuable agent in managing acute heart failure syndromes.
Clinical Uses
Milrinone is primarily used in the short-term management of acute decompensated heart failure, including cardiogenic shock. In cardiogenic shock, the heart’s ability to pump blood effectively is severely compromised, leading to inadequate tissue perfusion and life-threatening organ dysfunction. Milrinone’s inotropic and vasodilatory properties can help to improve cardiac output and reduce cardiac workload, thereby supporting blood pressure and organ perfusion.
Beyond cardiogenic shock, milrinone is also used in patients with severe heart failure who are unresponsive to conventional therapies such as diuretics and ACE inhibitors. It can be used as a bridge to cardiac transplantation or mechanical circulatory support devices. Furthermore, milrinone is used in pediatric patients with heart failure, particularly following cardiac surgery, where it can improve cardiac function and systemic perfusion. Its use in pediatric patients requires careful monitoring due to the potential for adverse effects.
Dosage
Milrinone is administered intravenously. Typical dosing guidelines are as follows:
Adults:
* Loading dose: 50 mcg/kg IV over 10 minutes.
* Maintenance infusion: 0.375-0.75 mcg/kg/min, titrated to effect.
Pediatrics:
* Loading dose: 50-75 mcg/kg IV over 15 minutes (may be omitted).
* Maintenance infusion: 0.25-0.75 mcg/kg/min, titrated to effect.
Dosage adjustments are often necessary based on renal function and clinical response. Careful hemodynamic monitoring is essential during milrinone administration.
Indications
* Short-term treatment of acute decompensated heart failure
* Cardiogenic shock
* Low cardiac output states post-cardiac surgery
* Bridge therapy for heart transplantation or mechanical circulatory support
Contraindications
* Hypersensitivity to milrinone or any of its components
* Severe hypovolemia (unless adequately corrected)
* Obstructive valvular heart disease (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy)
* Pulmonary hypertension (Milrinone can worsen pulmonary hypertension due to systemic vasodilation)
FAQ
Q: How does milrinone help in heart failure?
A: Milrinone improves heart failure by increasing the heart’s contractility (inotropic effect) and dilating blood vessels (vasodilatory effect), reducing the workload on the heart and improving blood flow.
Q: What are the common side effects of milrinone?
A: Common side effects include hypotension, arrhythmias (irregular heartbeats), thrombocytopenia (low platelet count), and headache.
Q: How is milrinone administered?
A: Milrinone is administered intravenously (IV) in a hospital setting, usually under close monitoring by healthcare professionals.
Q: Is milrinone safe for patients with kidney problems?
A: Milrinone clearance is reduced in patients with renal impairment. Dosage adjustments are necessary to avoid accumulation and potential toxicity.
Q: Can milrinone be used long-term?
A: Milrinone is typically used for short-term treatment of acute heart failure. Long-term use is generally not recommended due to potential adverse effects.
Q: What monitoring is required during milrinone infusion?
A: Continuous ECG monitoring, frequent blood pressure measurements, and monitoring of fluid status and electrolytes are essential during milrinone infusion. Platelet counts should also be monitored.
Q: Can milrinone be used in children?
A: Yes, milrinone can be used in children with heart failure, especially after cardiac surgery. However, careful monitoring and dosage adjustments are crucial due to the potential for adverse effects.
Q: What should I tell my doctor before receiving milrinone?
A: Inform your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements. Also, disclose any history of heart rhythm problems, low blood pressure, or kidney disease.
“`